BioAtrium AG
BioAtrium is an equally ownt joint Venture between Lonza and Sanofi
“The purpose of the Company is to construct, own and operate a mammalian biopharmaceutical cell culture production facility and to develop, manufacture and supply biopharmaceutical cell culture products.
CEO BioAtrium AG
Carlos Pereira
In BioAtrium we strive to help our customers by producing quality biologic drug substances.
We have a diverse and international corporate culture and are proud of our employees who contribute to the health of patients every day.
CFO BioAtrium AG
Stefan Heimsoth
In BioAtrium, we work as a team, incorporating digital technologies, to continuously improve our business processes in order to provide shareholders with a competitive production facility.
COO BioAtrium AG
Joe Kauten
BioAtrium marries cutting-edge science, technology and production with a strong team culture and personalized approach – led by Operations, Scientists, Quality and a diverse support team. Each day, it is a pleasure to come to work with so many diverse cultures, in the pursuit of improving the lives of our patients.
Chief Quality Officer BioAtrium AG
Ans Van Meensel
At BioAtrium, quality is at the heart of everything we do. As Chief Quality Officer, I am committed to ensuring that every product we manufacture meets the highest standards of quality, safety, and compliance. Behind every product are patients who rely on our medicines every single day, and that responsibility guides every decision we make. Our robust quality systems, experienced teams, and continuous focus on improvement enable us to maintain a reliable supply of safe and effective medicines.
BioAtrium a building complex
is created
BioAtrium is part of Lonza’s Ibex bioproduction complex in Visp: innovative technology, advanced automation and digital solutions. BioAtrium has the most modern large-scale production facilities and serves as a pioneer for future production standards.
Our Values
We share our values with LONZA and SANOFI.
Expertise in figures
Pictures
